 Seelos Therapeutics Inc NASDAQ: SEEL has amended the agreement with Vyera Pharmaceuticals AG, announced in March 2018, to develop SLS-002 to repurchase a significant portion of the royalties payable on any future net sales of SLS-002. As additional consideration under the prior agreement, Seelos has agreed to pay a mid-teens percentage royalty on any future net sales of SLS-002. 